Drug Profile

Research programme: purinoceptor P2X3 antagonists - Bellus Health

Alternative Names: NEO-5024; P2X3 receptor antagonists - Bellus Health

Latest Information Update: 03 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Developer BELLUS Health
Class Analgesics; Imidazoles; Pyridines; Small molecules
Mechanism of Action Purinergic P2X3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cough; Interstitial cystitis; Pain; Visceral pain

Most Recent Events

28 Jun 2023 BELLUS Health has been acquired by GSK
28 Apr 2021 No recent reports of development identified for preclinical development in Pain in Canada (PO)
28 Apr 2021 No recent reports of development identified for preclinical development in Visceral-pain in Canada (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com